

Special Issue

Enterovirus Vaccines Development and Immune Responses Following Immunization

Message from the Guest Editors

Currently, no effective vaccine is available against enteroviruses except for poliovirus and EV-A71. Although the EV-A71 vaccine has provided a powerful tool for containing HFMD outbreaks, cross-protection against other HFMD-associated enteroviruses has been very limited. Moreover, as the causative spectrum of HFMD has shifted, the prevalence of CVA6, CVA10, and CVA16 has significantly surpassed that of EV-A71. Therefore, vaccines against other pathogens urgently need to be developed. This Special Issue is intended to cover past and ongoing efforts to develop vaccines against enteroviruses. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but they are not limited to) the following: enterovirus vaccine development; immune efficacy of enterovirus vaccines; and challenges in enterovirus vaccine development.

Guest Editors

Dr. Yuefei Jin

Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China

Dr. Shuaiyin Chen

Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China

Deadline for manuscript submissions

28 February 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/204785

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).